Engineered Mesoporous Silica Reduces Long-Term Blood Glucose, Hba1C, and Improves Metabolic Parameters in Prediabetics

Abstract

<b>Aim:</b> To investigate the effect of oral consumption of engineered mesoporous silica particles, SiPore15^®, on long-term blood glucose levels and other metabolic parameters in individuals with prediabetes and newly diagnosed Type 2 diabetes. <b>Method:</b> An open-label, single-arm, multicenter trial was conducted in which SiPore15 was consumed three times daily for 12 weeks. Hemoglobin A1c (HbA1c, primary end point) and an array of metabolic parameters were measured at baseline and throughout the trial. <b>Result:</b> SiPore15 treatment significantly reduced HbA1c by a clinically meaningful degree and improved several disease-associated parameters with minimal side effects. <b>Conclusion:</b> The results from this study demonstrate the potential use of SiPore15 as a treatment for prediabetes that may also delay or prevent the onset of Type 2 diabetes.